When a deadly virus is spreading and there is no approved vaccine to stop it, every day counts. That is exactly the situation the world is facing right now and India is stepping in to help change it.
The Serum Institute of India, the Pune-based pharmaceutical giant that became a household name during the Covid-19 pandemic, has been chosen to manufacture clinical trial doses of an experimental Ebola vaccine being developed by the University of Oxford. The announcement comes backed by fresh funding from the Coalition for Epidemic Preparedness Innovations better known as CEPI which has committed up to $8.6 million to support the early development and preclinical testing of this vaccine candidate.
The urgency behind this move is very real. An outbreak of Bundibugyo ebolavirus, a particularly dangerous strain of the Ebola virus is currently spreading across the Democratic Republic of Congo and neighbouring Uganda. The situation has become serious enough that the World Health Organization has declared it a Public Health Emergency of International Concern, while the Africa Centres for Disease Control and Prevention has classified it as a Public Health Emergency of Continental Security. Hundreds of suspected cases and deaths have already been recorded, making this one of the largest filovirus outbreaks ever documented.
The Oxford vaccine candidate is built on a platform called ChAdOx1 the same core technology that powered the Oxford-AstraZeneca Covid-19 vaccine, which was produced in massive quantities by the Serum Institute during the pandemic. The familiarity between Oxford and SII is not coincidental. Their partnership during Covid-19 was one of the most significant vaccine manufacturing collaborations in modern history.
The $8.6 million in CEPI funding will specifically support the creation of a Master Virus Seed stock and the groundwork needed to prepare for Phase 1 clinical trials the first stage of human testing. Adar Poonawalla, CEO of the Serum Institute of India, made the company's commitment clear. "At moments like this, speed, scale and access is all that matters," he said, adding that SII would use its full manufacturing capabilities to move the vaccine forward rapidly while ensuring affordable access for the countries most affected, should the vaccine prove successful.
Professor Teresa Lambe, head of vaccine immunology at the Oxford Vaccine Group, confirmed that the programme is being pursued as a genuine global collaboration bringing together Oxford, CEPI, SII, and other international partners with a shared goal of bringing the outbreak under control.
It is worth noting that the Oxford-SII candidate is not the only vaccine being fast-tracked. CEPI's support forms part of a much larger push a $60 million-plus effort to accelerate three different experimental vaccines against the Bundibugyo strain simultaneously. Among them is a Moderna-led programme that has secured up to $50 million in funding. CEPI has deliberately selected candidates that use different vaccine technologies, maximising the chances that at least one will prove safe and effective in time to make a real difference.
The Ebola crisis unfolding in Central Africa is a stark reminder of how quickly an outbreak can escalate when the tools to fight it do not yet exist. What is different this time is that the global health community is not waiting to react it is moving fast, drawing on partnerships and platforms built during the pandemic, and throwing significant resources at the problem before it grows beyond control.
